In this Monday, July 27, 2020 file photo, a nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. On Tuesday, Sept. 8, 2020, the top executives of nine drugmakers likely to produce the first vaccines against the new coronavirus said that they will stick to the highest ethical and scientific standards in testing and manufacturing and will make the well-being of those getting vaccinated their top priority. (AP Photo/Hans Pennink)
By Linda A. Johnson
The top executives of nine drugmakers likely to produce the first vaccines against the new coronavirus signed an unprecedented pledge meant to boost public confidence in any approved vaccines.
The companies said Tuesday that they will stick to the highest ethical and scientific standards in testing and manufacturing and will make the well-being of those getting vaccinated their top priority.
The announcement comes amid worries that the U.S. Food and Drug Administration will be under political pressure to approve a vaccine before tests to prove it is safe and effective are finished.
Meanwhile, public health officials worry that if many Americans don't get the vaccine, it will be harder to reduce the spread of COVID-19.
The pledge was signed by the chief executive officers of American drugmakers Johnson & Johnson, Merck, Moderna, Novavax, and Pfizer, and European companies AstraZeneca, BioNTech, GlaxoSmithKline, and Sanofi. BioNTech has partnered with Pfizer on one of the vaccines now in the final round of human testing.
New car owner analysis from Insurify finds drivers spend an average of $5,851 a year on insurance, gas and maintenance alone, separate from financing costs.
Oil prices are climbing again after Saudi Arabia shut down a critical pipeline that has served as a major alternative route around the Strait of Hormuz.
Ryan Hamburger, Chief Commercial Officer at Instacart, explains how Clementine uses AI to personalize grocery shopping, build carts, find deals, and save time.
Ari Hawkins, Trade Reporter at POLITICO, examines Canada’s retaliation, Trump’s latest trade threats and the potential impact on businesses and consumers.
